%D8%B3%D9%8A%D9%81%D8%AA%D8%B1%D9%8A%D8%A7%D9%83%D8%B3%D9%88%D9%86%D8%B3%D9%81%D8%AA%D8%B1%DB%8C%D8%A7%DA%A9%D8%B3%D9%88%D9%86%E0%A6%B8%E0%A7%87%E0%A6%AB%E0%A6%9F%E0%A7%8D%E0%A6%B0%E0%A6%BF%E0%A6%AF%E0%A6%BC%E0%A6%BE%E0%A6%95%E0%A7%8D%E0%A6%B8%E0%A6%A8Category:CeftriaxoneCefftriacsonCeftriaxonCeftriaxoneCeftriaxona%D8%B3%D9%81%D8%AA%D8%B1%DB%8C%D8%A7%DA%A9%D8%B3%D9%88%D9%86KeftriaksoniCeftriaxoneCeftriaxonaCeftriaxon%D5%91%D5%A5%D6%86%D5%BF%D6%80%D5%AB%D5%A1%D6%84%D5%BD%D5%B8%D5%B6Ceftriaxone%E3%82%BB%E3%83%95%E3%83%88%E3%83%AA%E3%82%A2%E3%82%AD%E3%82%BD%E3%83%B3CeftriaxonumCeftriaxon%E0%AC%B8%E0%AD%87%E0%AC%AB%E0%AC%9F%E0%AD%8D%E0%AC%B0%E0%AC%BE%E0%AC%87%E0%AC%86%E0%AC%95%E0%AD%8D%E0%AC%B8%E0%AD%8B%E0%AC%A8CeftriaksonCeftriaxonaCeftriaxon%C4%83%D0%A6%D0%B5%D1%84%D1%82%D1%80%D0%B8%D0%B0%D0%BA%D1%81%D0%BE%D0%BDCeftriaksonCeftriaksonCeftriakson%E0%B9%80%E0%B8%8B%E0%B8%9F%E0%B9%84%E0%B8%95%E0%B8%A3%E0%B8%AD%E0%B8%B0%E0%B9%82%E0%B8%8B%E0%B8%99%D0%A6%D0%B5%D1%84%D1%82%D1%80%D1%96%D0%B0%D0%BA%D1%81%D0%BE%D0%BDCeftriaxoneQ421713%E9%A0%AD%E5%AD%A2%E6%9B%B2%E6%9D%BE
about
gonorrheaBruschtfiewerepididymitissepsisEscherichia coli infectious diseasegram-negative bacterial infectionLyme diseaseurinary tract infectionperitonitisotitis mediainfective endocarditisupper respiratory tract infectionchancroidstaphylococcal infectionbacterial meningitisbacterial pneumoniameningitisfemale reproductive system diseaseurinary tract infectionpelvic inflammatory diseasesinfectious bone diseaseenteritiscellulitisproctitis
P2176
P3781
Pharmacokinetic and Safety Study of HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone AdministrationErtapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)Pharmacokinetic of Ceftriaxone in Septic ICU PatientsCeftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal PneumoniaPrevention of Pneumonia Comparing Ceftriaxone With Subglottic AspirationCeftriaxone Versus Chloramphenicol for Treatment of Severe Pneumonia in ChildrenA Phase 3 Study Of Intravenous Metronidazole For Intrabdominal InfectionA Glutamate Transporter GLT1, in the Treatment of Bipolar DisorderComparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired PneumoniaEvaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective EndocarditisThe Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After AntibioticsA Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial PneumoniaCSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative BacteriaParamedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)Early-onset Ventilator-associated Pneumonia in Adults: Comparison of 8 Versus 15 Days of Antibiotic TreatmentSafety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric FeverIdentification of Gut Microbiome Biomarkers Associated to Acquisition of Enterobacteriae Highly Resistant to Third Generation Cephalosporines Following Ceftriaxone Treatment.Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed RepairPopulation Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care UnitsCeftobiprole in the Treatment of Pediatric Patients With PneumoniaOptimization of PK/PD Target Attainment for Ceftriaxone in Critically Ill Patients With Community-acquired Pneumonia.To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease DementiaImpact of Cefotaxime and Ceftriaxone on the Emergence and Carrying of Multidrug-Resistant BacteriaStudy to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection.Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative ColitisClinical Study of Anerning Particle for the Treatment of Childhood Community-acquired PneumoniaStudy of Lyme NeuroborreliosisA Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in AsiaPROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of CeftriaxoneInfant Severe Sepsis and Bacterial Meningitis in MalawiComparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of SBP in Patients With LCCeftriaxone in Non-neutropenic FeverEfficacy and Safety of Ertapenem Sodium (MK-0826) Following Colorectal Surgery in Chinese Adults (MK-0826-056)Chlamydia Trachomatis Immunology and Vaccinology StudyComparison Between Amoxycillin/Clavulanic Acid and Oxacillin/Ceftriaxone for Community Acquired-pneumoniaAntibiotic Treatment of Multiple Erythema MigransThe Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint InfectionEvaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
P4844
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivityNephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children.Design, synthesis, and biological evaluation of 4-alkyliden-beta lactams: new products with promising antibiotic activity against resistant bacteria.Characterisation of community acquired non-typhoidal Salmonella from bacteraemia and diarrhoeal infections in children admitted to hospital in Nairobi, Kenya.Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia: characterization of targets on platelets and red blood cells.A beta-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis.Comparative study on different recent diagnostic and therapeutic regimens in acute typhoid fever.Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.A year's review of bacterial pneumonia at the central hospital of Lucerne, Switzerland.[Antibacterial activity of ceftriaxone against various clinical strains isolated in 2004].Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.Ceftriaxone in febrile neutropenia.The beta-lactam antibiotic, ceftriaxone, attenuates morphine-evoked hyperthermia in rats.In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review.Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature.Occurrence and characterization of resistance to extended-spectrum cephalosporins mediated by beta-lactamase CMY-2 in Salmonella isolated from food-producing animals in CanadaEffects of ceftriaxone on ethanol, nicotine or sucrose intake by alcohol-preferring (P) rats and its association with GLT-1 expressionUpregulation of GLT1 attenuates cue-induced reinstatement of cocaine-seeking behavior in rats.A meta-analysis of randomized, controlled trials assessing the prophylactic use of ceftriaxone. A study of wound, chest, and urinary infections.Clinical features of bacterial meningitis in Italy: a multicenter prospective observational study.Prevalence of antimicrobial resistance in Neisseria gonorrhoeae in an HIV/AIDS clinic.Epidemiology of typhoid and paratyphoid fever in Kathmandu: two years study and trends of antimicrobial resistance.Epiglottitis in the Hemophilus influenzae type B vaccine era: changing trends.High incidence of penicillin resistance among alpha-hemolytic streptococci isolated from the blood of children with cancer.Ceftriaxone-induced toxic hepatitis.Cross-reactivity in β-Lactam Allergy.Prevalence, species differentiation, haemolytic activity, and antibiotic susceptibility of aeromonads in untreated well water.Degeneracy and additional alloreactivity of drug-specific human alpha beta(+) T cell clones.Oral ceftibuten switch therapy for acute pyelonephritis in children.The isolation of antibiotic-resistant salmonella from retail ground meats.Time-kill evaluation of antimicrobial regimens against clinical isolates of penicillin-resistant Streptococcus pneumoniae.[Community-acquired bacteremia]Antimicrobial resistance among invasive Haemophilus influenzae strains: results of a Brazilian study carried out from 1996 through 2000.Clinical characteristics of invasive Haemophilus aphrophilus infections.beta-Lactam allergenic determinants: fine structural recognition of a cross-reacting determinant on benzylpenicillin and cephalothin.Ceftriaxone (1 g intravenously) penetration into abdominal tissues when administered as antibiotic prophylaxis during nephrectomy.Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child.Synthesis, characterization and immunochemical evaluation of cephalosporin antigenic determinants.[Guideline 'Lyme borreliosis'].Antimicrobial drug use in hospitalised paediatric patients: a cross-national comparison between Germany and Croatia.
P921
Q101896-44A3C131-5D46-48F2-8E28-17E575816813Q101896-A325E367-E659-4732-95EA-B1C8C0171764Q12192-841E1ABD-0994-40D5-A47E-5B2D41AEE369Q1344812-ADC8B61A-03B4-41A3-9099-BED769D73BEAQ183134-94B1C186-44B9-40CD-B011-08A100A3E11AQ18975220-D5FC2E15-D7A3-4464-B06C-B28D28D87907Q19597369-5359693E-E751-43FE-AE1C-3DFB66B015D2Q201989-1C229701-390D-4A13-8617-583461195D95Q221668-30DCFC11-CB2D-471F-9649-92CCEC2B5FFAQ221668-33654AD6-C4E0-4DEF-95C9-BFEBDE19226CQ223102-393D4622-1C84-433C-B726-CB1BDA33261DQ223254-BFD8C65C-1BBD-49FE-B539-44712D835CECQ223254-EE06E441-5D36-4BD1-8C81-C721E680D5BBQ2450598-658BDE78-BDE0-42A8-BC83-2624A93052A5Q2622199-F40BFADE-CE57-455B-A22F-1EA84CF817D6Q31798-1E5B2626-2E75-4117-87A7-5C6F70CF3149Q34879-04B4D5E9-AF51-427F-B45C-DEC994ABF488Q3678510-9C68DC5B-55DC-477E-8649-9C7ABB399ECEQ3776920-2DDFC70D-E799-443F-8B11-ED4F20F791D4Q48143-3B6FCEE3-58B4-49FB-880E-41DAE89F2AADQ48143-A29B928D-C56A-4005-9928-26D9069382D1Q5442760-AB257EEC-BC89-4261-B111-4EED9BD103B8Q55779861-D023B4CD-5018-484F-9D65-DC935606DD6DQ558070-CBFC1DF6-EBEA-4A8E-99B7-9BFDB0BF5581Q6029216-95CEF25E-2876-4947-9B80-F3068DA4BB32Q854353-FB400167-7B66-46FD-AC7C-754B5FD381F6Q876887-D9691772-B8C0-4182-A99D-4C0FEC2AE56FQ941770-407E43F8-57AB-42F7-BD34-0C35CBE84EA8
P2176
Q61917823-A2E9D675-6728-4DB6-9F1A-38F2B8DE5956Q61920964-DA3FEC49-B694-4ADE-89ED-7D054F7686A9Q61921131-5DF53741-2070-4839-BBAE-3EF7723C2038Q61921141-85E7F12D-C727-4C81-812D-68311F59A032Q61932442-93E5B6A5-9CF0-4C89-8917-1039E55A3864Q61932968-D8DA0098-AC29-466B-96F2-9C85F153604AQ61955314-BB9291AF-110C-4335-8CA2-F8CE6DEF3851Q61979021-BFAE1E3E-6FEF-4CA8-9B20-CB0BC0881479Q61979487-9B2DA947-DD1C-4D54-88B3-EAE1F288E5FAQ62054905-4BE9F323-1BAF-4D66-BA23-CEEA02E84E15Q62062586-EDE58A8C-1A8C-4C6D-B6DB-6EB7FC64DE62Q62105123-FC9FBB2A-C8E6-4DFC-84C0-63C2060374FBQ62813020-A0CCE384-522E-4BAB-97B1-CF1E4D07DA65Q63229244-4EEE5E65-3B43-4F69-B531-61D1FEFFAAFEQ63316905-95F4915B-D15F-4D9C-822E-1910EBCF971FQ63316963-00B16608-2FB4-4AEE-B096-42FAF096689FQ63322047-FBBE92D4-2B12-42E9-AFC2-8F077F8AA614Q63397552-F7F21F63-959D-4BDC-BE91-7815E144F6A1Q63400911-EA670AEC-901A-4E92-BB8D-23E0E8CD058CQ63401107-17130D57-C172-423A-9DED-1D1AB27CFBA0Q63401347-10062C6E-94F3-4657-8139-9F23B64FC1E0Q63401381-E9FFA2B3-6CC0-42E3-9081-E022C5C30B22Q63401803-5E009291-7B29-4C2B-A058-266EC5E1EE51Q63577572-BA14E2A3-787E-4971-A9DC-FA45DEBE18E2Q63580507-1456B92B-36AB-4756-97CE-F322C1CE9C5DQ63593348-959DDA55-004A-4EF8-841F-615EFB408D14Q63597282-EE504DBA-F6EE-4E8C-9208-547EB63C25C7Q63808029-39193C67-38C6-4B97-85D4-6C67F58D215AQ63812992-33A540A3-6FDE-4EE4-AB0E-43C0A5652B31Q63813452-A206171A-325D-4B90-8E35-C5917583373FQ63815525-715ABD7B-C00A-4620-8942-A0A2E5923259Q63816808-9FDBD46E-095A-40ED-A8A3-2F928BCE6BDDQ63817005-C164FC89-89C6-425A-A861-E8DA197E12EEQ63818426-569E3103-4D24-40B3-861E-6186631460CAQ63829575-9BF769E0-BC9C-44F5-ACA4-DF2C6637A871Q63832744-44CA4B7C-CBBA-4D54-A6C8-5B7FF72A75F1Q63833399-C0494310-1577-42FC-B490-659001E30997Q63834246-A333A96B-822C-43F6-A743-1DCE9821C756Q63838117-1D0323C7-C29E-461B-B0F4-3798AAAF286EQ63840490-3FDCEDC8-F5A5-46D3-8444-752EE29ECC68
P4844
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Ceftriakson
@sh
Ceftriakson
@sl
Ceftriaxon
@de
Ceftriaxona
@gl
Ceftriaxone
@nl
Ceftriaxone
@vi
Ceftriaxonum
@la
Ceftriaxonă
@ro
Keftriaksoni
@fi
cefftriacson
@cy
type
label
Ceftriakson
@sh
Ceftriakson
@sl
Ceftriaxon
@de
Ceftriaxona
@gl
Ceftriaxone
@nl
Ceftriaxone
@vi
Ceftriaxonum
@la
Ceftriaxonă
@ro
Keftriaksoni
@fi
cefftriacson
@cy
altLabel
(6R,7R)-7-{[(2Z)-2-(2-amino-1, ...... .0]oct-2-ene-2-carboxylic acid
@cy
(6R,7R)-7-{[(2Z)-2-(2-amino-1, ...... .0]oct-2-ene-2-carboxylic acid
@en
73384-59-5
@fr
C18H18N8O7S3
@en
C18H18N8O7S3
@fr
C18H18N8O7S3
@it
Cefatriaxone
@en
Ceftriaxona
@en
Ceftriaxone
@en
Ceftriaxone
@es
prefLabel
Ceftriakson
@sh
Ceftriakson
@sl
Ceftriaxon
@de
Ceftriaxona
@gl
Ceftriaxone
@nl
Ceftriaxone
@vi
Ceftriaxonum
@la
Ceftriaxonă
@ro
Keftriaksoni
@fi
cefftriacson
@cy